E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 9/1/2005 in the Prospect News Biotech Daily.

Targeted Genetics amends Biogen funding agreement, pushing out debt repayments

By Sara Rosenberg

New York, Sept. 1 - Targeted Genetics Corp. amended its funding agreement with Biogen Idec Inc. to restructure the repayment of outstanding debt that was due over the next year of about $10.7 million, according to an 8-K filed with the Securities and Exchange Commission Thursday.

Under the amended agreements, Targeted Genetics made an initial payment on Thursday to Biogen Idec of $2.5 million, and agreed to make additional payments of about $3.1 million in August 2007 and $2.5 million in each of August 2008 and August 2009.

As part of the restructuring agreement, Targeted Genetics has agreed to apply one-third of certain up-front or milestone payments received from potential corporate collaborations to repayment of the outstanding debt.

In addition, Targeted Genetics granted Biogen Idec a right of co-sale in certain equity financings approved by Targeted Genetics' board of directors before Nov. 30, and Biogen Idec agreed not to sell any of its shares of common stock until the earlier of Nov. 30, and the completion of such a sale.

Biogen Idec also agreed to enter into an additional lock-up agreement if Targeted Genetics completes an equity financing before Nov. 30.

"The successful renegotiation of this debt with Biogen Idec provides us a more manageable debt structure and is clearly an important component of our overall long-term financing strategy," said H. Stewart Parker, president and chief executive officer, in a company news release. "We are managing our cash position carefully and continue to look for ways to leverage value from our capabilities to build additional financial resources."

Targeted Genetics is a Seattle-based biotechnology company.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.